SCN1A

SCN1A

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SCN1A</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>SCN1A</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>2q24.3</td>
</tr>
<tr>
<td class="label">Genomic Coordinates</td>
<td>chr2:165,990,000-166,100,000 (GRCh38)</td>
</tr>
<tr>
<td class="label">Gene Length</td>
<td>~190 kb</td>
</tr>
<tr>
<td class="label">Number of Exons</td>
<td>26 coding exons</td>
</tr>
<tr>
<td class="label">Transcript Length</td>
<td>~7.2 kb coding sequence</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>2,009 amino acids</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Voltage-gated sodium channel alpha subunit</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (neurons, particularly GABAergic interneurons), heart</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>182389</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>P35499</td>
</tr>
<tr>
<td class="label">Disorder</td>
<td>Variant Type</td>
</tr>
<tr>
<td class="label">Dravet syndrome</td>
<td>Missense, nonsense, splice, large del</td>
</tr>
<tr>
<td class="label">GEFS+ (Genetic epilepsy with febrile seizures plus)</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">Febrile seizures (isolated)</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">Intractable childhood epilepsy with generalized tonic-cloni

SCN1A

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">SCN1A</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>SCN1A</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>2q24.3</td>
</tr>
<tr>
<td class="label">Genomic Coordinates</td>
<td>chr2:165,990,000-166,100,000 (GRCh38)</td>
</tr>
<tr>
<td class="label">Gene Length</td>
<td>~190 kb</td>
</tr>
<tr>
<td class="label">Number of Exons</td>
<td>26 coding exons</td>
</tr>
<tr>
<td class="label">Transcript Length</td>
<td>~7.2 kb coding sequence</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>2,009 amino acids</td>
</tr>
<tr>
<td class="label">Protein Class</td>
<td>Voltage-gated sodium channel alpha subunit</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain (neurons, particularly GABAergic interneurons), heart</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>182389</td>
</tr>
<tr>
<td class="label">UniProt</td>
<td>P35499</td>
</tr>
<tr>
<td class="label">Disorder</td>
<td>Variant Type</td>
</tr>
<tr>
<td class="label">Dravet syndrome</td>
<td>Missense, nonsense, splice, large del</td>
</tr>
<tr>
<td class="label">GEFS+ (Genetic epilepsy with febrile seizures plus)</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">Febrile seizures (isolated)</td>
<td>Missense</td>
</tr>
<tr>
<td class="label">Intractable childhood epilepsy with generalized tonic-clonic</td>
<td>Various</td>
</tr>
</table>

[SCN1A](/entities/scn1a) encodes Nav1.1, a voltage-gated sodium channel alpha subunit expressed predominantly in inhibitory GABAergic interneurons throughout the central nervous system. Pathogenic variants in [SCN1A](/entities/scn1a) are the leading genetic cause of Dravet syndrome, accounting for ~70-80% of cases. The gene is also associated with genetic epilepsy with febrile seizures plus (GEFS+), febrile seizures, and other epilepsy phenotypes.

[SCN1A](/entities/scn1a) is one of the most commonly tested genes in pediatric epilepsy, and the discovery of [SCN1A](/entities/scn1a) variants in a patient with early-onset seizures has become nearly diagnostic for Dravet syndrome[@scn1a2018].

Gene Information

Structure and Function

Nav1.1 Protein Structure

Nav1.1 is composed of four homologous domains (I-IV), each containing six transmembrane segments (S1-S6):

• S1-S4: voltage-sensing domain — S4 carries the positively charged residues that detect membrane depolarization
• S5-S6: pore-forming domain — S5-S6 line the ion-conducting pore
• S4-S5 linker: couples voltage sensing to pore opening
• C-terminal tail: regulatory and interaction domains

Channel Function

Nav1.1 contributes to the upstroke of the action potential in neurons, particularly in inhibitory interneurons. Unlike channels in excitatory neurons (where Nav1.2 and Nav1.6 dominate), Nav1.1's kinetics and localization make it particularly critical for the sustained firing of fast-spiking interneurons that regulate circuit excitability.

The channel operates in three states:

Inhibitory interneurons rely on Nav1.1 for rapid, sustained firing that provides feedforward and feedback inhibition. Loss of Nav1.1 reduces this inhibitory drive, leading to hyperexcitable circuits.

Pathophysiology in Dravet Syndrome

Loss-of-Function Mechanism

Dravet syndrome is fundamentally a loss-of-function disorder. Over 1,000 pathogenic variants have been identified, all resulting in reduced functional Nav1.1 channels:

The key paradox: despite being expressed throughout the brain, [SCN1A](/entities/scn1a) loss preferentially affects GABAergic interneurons rather than excitatory pyramidal neurons. This "interneuronopathy" model explains why SCN1A variants cause epilepsy rather than a channelopathy affecting motor or sensory function.

Interneuron Specificity

The specificity of Nav1.1 for interneurons likely reflects:

• Higher Nav1.1 density in interneurons relative to other sodium channels
• Unique firing patterns of interneurons (fast-spiking) that require Nav1.1's kinetic properties
• Developmental compensation in excitatory neurons (Nav1.2/Nav1.6 can substitute)

Network Consequences

• Reduced GABAergic inhibition → network hyperexcitability → seizures
• Seizures during critical developmental windows → irreversible circuit rewiring
• Ongoing interneuron stress → progressive dysfunction
• Secondary effects on excitatory circuits → cognitive impairment

Disease Associations

Genotype-Phenotype Correlations

• Missense variants in the pore region (S5-S6): more likely severe Dravet phenotype
• Missense variants in the voltage sensor (S4): may produce milder GEFS+ phenotype
• Truncating variants (nonsense, frameshift): typically cause severe Dravet
• Large deletions encompassing [SCN1A](/entities/scn1a): severe phenotype, may include developmental delay, dysmorphic features

Therapeutic Targets

ASO Approaches (STK-001)

Stoke Therapeutics developed STK-001, an allele-specific antisense oligonucleotide that increases SCN1A mRNA and Nav1.1 protein expression from the wild-type allele. By upregulating the normal copy of the gene, STK-001 compensates for the loss of function from the pathogenic variant. See [STK-001 clinical trial page](/clinical-trials/stk001-dravet-syndrome-phase-1-2) and [therapeutics hub page](/therapeutics/aav-gene-therapy-neurodevelopmental-epilepsy).

Gene Activation (ETX101)

Encoded Therapeutics developed AAV9-delivered CRISPR-activation (CRISPRa) constructs targeting the SCN1A promoter region to increase endogenous expression. This approach does not require allele specificity — any patient with one functional allele could benefit. See [ETX101 clinical trial page](/clinical-trials/etx101-encoded-therapeutics-dravet-syndrome).

Gene Replacement

Full-length SCN1A (~6kb coding) approaches AAV packaging limits. Strategies include:

• Mini-gene constructs (functional truncation)
• Dual-vector approaches (split-intein trans-splicing)
• Regulation element optimization to fit in smaller construct

Base Editing

With ~40% of Dravet patients having missense variants, precision base editing could correct individual point mutations. Beam Therapeutics and academic groups are developing base editors for SCN1A missense mutations.

Research and Open Questions

References

Pathway Diagram

The following diagram shows the key molecular relationships involving SCN1A discovered through SciDEX knowledge graph analysis:

Pathway Diagram

The following diagram shows the key molecular relationships involving SCN1A discovered through SciDEX knowledge graph analysis: